06/12/2019
New Class of Life-Extending Drugs for Men with Metastatic Hormone-Sensitive Prostate Cancer
At the 2019 American Society of Clinical Oncology (ACSO) Annual Meeting, results presented by two PCF-funded investigators from pivotal phase 3 clinical trials will likely lead to approval of a new class of life-extending treatment options for men with metastatic hormone-sensitive prostate cancer (mHSPC). mHSPC refers to men whose prostate... Read More
02/14/2018
FDA Approves Apalutamide (Erleada); the first treatment for non-metastatic castration-resistant prostate cancer
February 14, 2018 – Today the U.S. Food and Drug Administration (FDA) approved apalutamide (Erleada, also previously called ARN-509) for the treatment of non-metastatic castration-resistant prostate cancer (non-metastatic CRPC). This clinical setting is when men who are being treated with androgen deprivation therapy (ADT) see their PSA levels begin to... Read More
02/09/2018
Two new treatments have been found for prostate cancer patients who previously had no effective treatment options
Over the course of prostate cancer progression, there can come a time during which the cancer is progressing, but there are no treatments known to improve survival. One of these “empty spaces” is when men who are being treated with androgen deprivation therapy (ADT) see their PSA levels begin to... Read More
12/15/2017
Experts create guidelines for screening prostate cancer patients for inherited cancer risk genes
The genes you inherited from your parents can play an important role in determining your risk for developing prostate cancer. Research led by PCF-funded investigators and others have identified several inherited genes that drive the development of not only prostate cancer in general, but more aggressive forms. These genes can... Read More
07/07/2017
Precision medicine study finds new treatment for untreatable subtype of advanced prostate cancer
A clinical trial reported on at the 2017 American Society of Clinical Oncology (ACSO) Annual Meeting found that advanced prostate cancer patients whose tumors have a certain combination of mutations may significantly benefit from treatment with platinum chemotherapy. Not all “chemotherapy” is the same. Taxane chemotherapy (docetaxel, cabazitaxel) which works... Read More
06/29/2017
Combination of two new therapies may be highly effective in advanced prostate cancer
Early results from a clinical trial presented at the 2017 American Society of Clinical Oncology (ACSO) Annual Meeting found that combining an immunotherapy with a targeted therapy may be highly effective in patients with advanced prostate cancer. Checkpoint immunotherapy, a treatment that reboots hibernating tumor-killing immune cells, has produced remarkable,... Read More
06/09/2017
PCF study finds that adding a 22-gene test to standard prostate cancer risk groups improves accuracy of patient prognosis
A PCF study presented at the 2017 American Society of Clinical Oncology (ACSO) Annual Meeting found that using a 22-gene test along with standard prostate cancer risk group features vastly improves predictions of how aggressive a patient’s cancer is – enabling clinicians to choose more appropriate therapies and better avoid... Read More
06/07/2017
Cancer patients who self-report symptoms to their doctors on a weekly basis live five months longer
A provocative study at the 2017 American Society of Clinical Oncology (ACSO) Annual Meeting reported that metastatic cancer patients who self-reported their symptoms to their doctors on a weekly basis lived 5.2 months longer on average, likely due to more proactive symptom management. Dr. Ethan Basch, a medical oncologist at... Read More
06/06/2017
Abiraterone and Enzalutamide equivalent as first-line therapy in metastatic hormone therapy- resistant prostate cancer
A clinical trial reported on at the 2017 American Society of Clinical Oncology (ACSO) Annual Meeting found that men who develop metastatic hormone therapy-resistant prostate cancer (mHRPC) have similar outcomes if prescribed either abiraterone or enzalutamide. Abiraterone and enzalutamide are two hormonal therapies that can be used as first line... Read More
05/26/2017
FDA approves first precision medicine for the treatment of cancers with certain genetic defects, including prostate cancer
On May 23, 2017, the field of precision medicine achieved a major milestone with the FDA’s first ever approval of a cancer therapy based entirely on a tumor’s unique characteristics and not where the tumor developed in the body. In other words, while therapies to date have been approved for... Read More